June 3, 2022 7:58am

Sector equities are cheap but, share pricing is continually suspect

Seems that algorithms usually stimulate a “Quickening”, so who or which equity is going to lose its share pricing head?

Pre-open indications: 3 Upside Indications, 5 Downside Indications, 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.49% (-163 points), S&P futures are DOWN -0.72% (-30 points) and NASDAQ futures are DOWN -1.13% (-145 points) early in the pre-open – so far,


Stock futures were lower Friday morning with May jobs report (employment data) due out at 8:30 a.m. ET,

European markets rose slightly,

Asia-Pacific markets also rose



Yesterday, all three major indexes snapped two-day losing streaks, putting them on pace for a winning week. The Dow added 435.05 points, or 1.33%, the S&P 500 gained 75.59 points or +1.84% while the Nasdaq advanced 322.44 points or +2.7%.

Thursday’s gains pushed the major averages into the green for the week.

Economic Data Docket: today’s nonfarm payroll report is the “tell’ for the market and sector; also reporting, new purchasing managers’ index data from Markit and ISM. ADP “readings” showed the slowest job creation pace of the pandemic-era recovery.

  • Attributable quote concerning, “A very strong reading might signal that the Fed has a lot more to do to quell inflationary pressures in the economy, while a big negative surprise – like we saw in ADP today – could support those who think the U.S. is fast slipping into a recession.” <Goldman Sack’s Chris Hussey>


RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector shook-off the downward spiral. As I wrote this a.m., the wall of worry was to be climbed; investor fatigue still facilitates diminished investor sentiment. As usual, more frequently right than wrong as I never leave investors uninformed”https://www.regmedinvestors.com/articles/12457


Ebb and flow –

Q2/22 –

June – 1 positive and 1 negative close

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628 - added Mesoblast (MESO)


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Exhibiting positive indication:

Vericel (VCEL) closed up +$1.21 to $27.53 <52-week low of $25.11> after Wednesday’s -$0.83 and Tuesday’s-$0.82 with a positive +$0.27 or +0.98% pre-open indications,

Fate Therapeutics (FATE) closed up +$0.73 to $23.36 <52-week low of $20.49> after Wednesday’s $22.63, Tuesday’s $23.110 following the previous Friday’s $23.58 with a positive +$0.33 or +1.41% pre-open indication,

Global Blood Therapeutics (GBT) closed up +$0.99 to $25.01 <52-week low of $22.67> after Wednesday’s -$0.92 and Tuesday’s -$1.21 with a positive +$0.31 or +1.24% pre-market indication,


Exhibiting negative indications:

Beam Therapeutics (BEAM) closed up +$2.82 to $36.85 after Wednesday’s $34.03 and Tuesday’s $35.18 following the previous Friday’s $36.07 with a negative -$0.16 or -0.43% pre-open indication,

Editas Medicine (EDIT) closed up +$0.57 to $11.54 after Wednesday’s -$0.42 and Tuesday’s -$0.29 with a negative -$0.15 or -1.30% pre-open indication,

Intellia Therapeutics (NTLA) closed up +$1.81 to $44.67 after Wednesday’s $42.86, Tuesday’s $46.14 following the previous Friday’s $48.75 with a negative -$0.46 or +1.03% pre-open indication,

Ultragenyx (RARE) closed up +$3.82 to $49.96 <52-week low of $45.20> after Wednesday’s -$0.76 and Tuesday’s -$1.74 with a negative -$0.46 or -0.92% pre-open indication,

UniQure NV (QURE) closed up +$0.51 to $14.67 <52-week low of $12.52> after Wednesday’s $14.16 and Tuesday’s $14.36 following the previous Friday’s $14.90 with a negative -$0.57 or -3.89% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat with 1 share traded after Wednesday’s -$0.37 to $4.75 with 100 shares traded after Tuesday’s -$0.22 with 330 shares traded after having traded with six (6 – May 20 to May 27) sessions being flat.

  • WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.  is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?


The BOTTOM LINE: It’s Friday following a roller-coaster week … hop-on for another ride

The cell and gene therapy sector suffered and celebrated:   

·         Thursday with a positive close of 28/6 and 1 flat,

·         Wednesday ended with a negative close of 6/29 and 1 flat.

·         Tuesday ended with a negative close of 7/28.

·         Monday was a market holiday.

·         The previous Friday ending with a positive close of 33/1 and 1 flat.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resilience or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

I am not always right but, more than frequently not wrong … I just DO NOT trust this market … too much fear and panic. This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

I have NOT seen ANY step-up of declining company investment by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

I caution investors that the severe share pricing’s – technical and fundamental damage has been suffered these past several months which will take longer than a few good sessions to repair.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.